Eli Lil­ly ax­es an ear­ly-stage PD-L1/TIM-3 bis­pe­cif­ic pro­gram in lat­est pipeline cleanup

Three months af­ter Eli Lil­ly $LLY fol­lowed up on its move to high­light a se­lect group of can­cer drugs in the pipeline with the elim­i­na­tion of 2 mid-stage on­col­o­gy pro­grams, the phar­ma gi­ant is bring­ing out the ax to lop off an ear­ly-stage PD-L1/TIM-3 bis­pe­cif­ic.

Its Q2 up­date to­day notes that the bis­pe­cif­ic is be­ing swept out along­side an an­ti-in­flam­ma­to­ry pro­gram for IL-23/CGRP in im­munol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER